Introduction
Pancreatic cancer has the highest death rate to incident ratio of cancers in the USA (1) . The pathogenesis of pancreatic cancer is complex and seems to involve environmental influences and genetic alterations.
Transforming growth factor (TGF)-b1 over-expression is associated with poor survival in patients with pancreatic cancer (2) . It often suppresses early tumorigenesis but later enhances tumor progression (3) (4) (5) . Although TGFb1 exerts an inhibitory effect on cancer cell growth in vitro, it also stimulates the synthesis of the extracellular matrix and has been implicated in the regulation of cell differentiation, angiogenesis, immunosuppression and fibrosis (6) .
TGFb signals through a heterotetrameric receptor complex comprising type II receptors and type I receptors, both serine/threonine kinases (7), followed by a canonical SMAD-dependent signaling cascade (8). Several studies have shown that expression of dominantnegative (DN) transforming growth factor-b receptor type 2 constructs in mice lead to enhanced mammary tumorigenesis with or without carcinogens (9) (10) (11) . Moreover, results obtained from conditional ablation of SMAD4 in mouse mammary epithelium (12) confirm the importance of signaling through the TGFb/SMAD pathway during tumor initiation and progression as suggested in earlier reports of enhanced colon tumorigenesis in SMAD4-null mouse models (13, 14) . These effects, however, are not limited to the mammary gland and colon since DN transforming growth factor-b receptor type 2 expression in the lung and skin also resulted in enhanced carcinogeninduced tumorigenesis (11, 15) .
The genetic profile of pancreatic cancer suggests contribution from both oncogenes and tumor suppressor genes. The tumor suppressor SMAD4 is deleted from .64% of pancreatic cancers (16, 17) , removing this TGFb signaling molecule from the majority of these tumors. K-RAS is mutated in .90% of pancreatic cancers, although the presence of oncogenic K-RAS is not specific to cancer as it can also be found in benign pancreatic lesions (18, 19) . Numerous reports have described a correlation between RAS transformation and deficient TGFb responsiveness, particularly with regards to TGFb anti-mitogenic responses. RAS transformation of lung, intestinal, liver or mammary epithelial cells confers resistance to growth inhibition by TGFb (20, 21) . Kretzschmar et al. (22) showed that oncogenic RAS inhibits the TGFb signal transduction pathway at the level of SMAD by RAS/ ERK-induced phosphorylation of clusters of four Ser/Thr-Pro sites in the linker region of SMAD2 and SMAD3 and preventing accumulation of SMAD2 and SMAD3 in the nucleus and inhibiting TGFb signaling.
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN), also known as MMAC1/TEP1, is localized to chromosome 10q23 (23, 24) . It is a dual specificity phosphatase and antagonizes phosphoinositide-3-kinase (PI3K)/ATP-dependent tyrosine kinases (Akt) signaling pathway (25) , and thus plays a functional role in cell cycle arrest and apoptosis (26, 27) . Description of germ line mutations and deletions of PTEN in two hereditary cancer predisposition diseases, Cowden Disease and the Bannayan-Riley-Ruvalcaba syndrome (28) (29) (30) (31) , point to a role of PTEN as a tumor suppressor gene in the pathogenesis of both benign and malignant growth. PTEN is one of the most frequently mutated proteins in a variety of cancers (23, 24, 32) , but PTEN mutations rarely occur in pancreatic cancer (33) . PTEN expression has been shown to be regulated by TGFb1 in keratinocytes (34) , and PTEN mRNA levels were also reduced in a model of TGFb1 over-expressing transgenic mice that develop pancreatic fibrosis (35) . Reduction of PTEN mRNA levels in pancreatic cancer cells following TGFb1 treatment has also been reported (35) . Although PTEN is not found mutated in pancreatic cancers, the reduction of its expression may give pancreatic cells an additional growth advantage.
Our present study focused on whether TGFb modulates PTEN expression in SMAD4-null pancreatic cancer cells and whether that modulation was influenced by oncogenic K-RAS. This investigation may provide clues to the conversion of TGFb function from that of a tumor suppressor in early carcinogenesis to one of a tumor promoter in more mature cancers. Both SMAD4 loss and K-RAS activation are typical findings in pancreatic cancers. We found that TGFb reduces PTEN expression in the absence of SMAD4, and oncogenic K-RAS and downstream effectors potentiate TGFb-suppressed PTEN expression. Inhibition of K-RAS or its downstream effectors functionally 'switched on' PTEN expression where it may promote tumor suppression.
Materials and methods
Materials and reagents PD98059, a MEK inhibitor, was purchased from PharMingen (San Diego, CA). A solution of PD98059 in dimethyl sulfoxide (Sigma, St Louis, MO) was prepared and used after diluting with medium for each assay. Dimethyl sulfoxide was also used as a blank control. DN construct of K-RAS was a generous gift from Dr Rik Derynck (University of California, San Francisco, CA).
Cell cultures
BxPC-3 and CAPAN-1 cells were obtained from American Type Culture Collection and they were maintained in RPMI and Dulbecco's modified Eagle medium (Gibco BRL, Gaithersburg, MA), respectively, supplemented with 10% fetal calf serum (Gibco BRL), without any antibiotics in an incubator at 37°C and 5% CO 2 . To analyze the effect of TGFb1 on PTEN expression and cell proliferation, pancreatic cancer cell lines were grown to 70-80% confluency in the corresponding medium containing 10% fetal bovine serum. Afterwards, cells were washed twice in phosphate-buffered saline, starved for 30 min in serum-free medium and finally treated for 24 and 48 h with 10 ng/ml TGFb1 or medium alone.
Cell growth assay
For determination of cell number, 30 000 human pancreatic carcinoma cells per well were seeded onto six-well plates (Nunc, Wiesbaden, Germany), and incubated overnight in complete growth medium (RPMI 1640 þ 10% fetal bovine serum). Complete medium was replaced with serum-depleted medium with or without TGFb and/or inhibitors. Cell numbers from each well were determined every 24 h for 3 days. Up to 12 independent experiments were performed.
Transfection of the CAPAN-1 cells
One day before transfection, exponentially growing cells were trypsinized, and 1-2 Â 10 6 cells were plated onto 10 cm Petri dishes. Cells were then transfected the next day with the DN K-RAS construct or empty vector. The DN construct is known to suppress activated RAS by blocking RAS guanine nucleotide exchange factors (36) . Transfection was carried out using Transfast (Promega, Madison, WI). Briefly, plasmid DNA was mixed with serum-free medium, followed by transfection reagent at the charge ratio of 1:1. The mixture was allowed to react for 10-15 min, and it was transferred to the cells to be transfected. One hour after transfection, complete medium was overlaid on top of the cells and allowed to incubate for 48 h.
Total RNA extraction and semi-quantative reverse transcriptase-polymerase chain reaction Total RNA extraction from the control and TGFb-treated cells was conducted using Trizol reagent (Invitrogen Corporation, Carlsbad, CA). Cells grown on six-well plate were lysed with the reagent (1 ml per well). Lysates were combined with chloroform, mixed and the pellets precipitated with isopropanol and 75% ethanol and air-dried. Total RNA was then extracted and re-suspended in water. Two micrograms of total RNA were reversed transcribed into cDNA and amplified by polymerase chain reaction (PCR) for PTEN and SMAD4 expression (SuperScript II, Invitrogen Corporation). Briefly, following inactivation at 65°C for 10 min, 1 ll of the reaction mixture were incubated in buffer containing 0.2 mM concentrations of dATP, dCTP, dGTP, dTTP, 0.2 lM concentrations each of oligonucleotide primers, 3 mM MgCl 2 and a 10Â buffer consisting of 200 mM Tris-HCl (pH 8.0), 500 mM KCl and 1 U Taq polymerase. PCR primers were designed to amplify a region spanning from nucleotides 117 to 741 of the PTEN gene (forward strand, 5#-CAGAA-AGACTTGAAGGCGTAT-3# and reverse strand, 5#-AACGGCTGAGGGAA-CTC-3#), as described previously (37) . The 624 bp fragment contains an NsiI restriction site allowing to distinguish this region from the PTEN pseudogene (37) . PCR primers used to amplify SMAD4 were forward strand, 5#-AACGT-TAGCTGTTGTTTTTCAC-3#and reverse strand, 5#-AGAGTATGTGAAGA-GATGGAG-3#. The conditions for PCR reactions of PTEN were as follows: denaturation at 95°C for 3 min and 35 cycles of 94°C for 30 s, 55°C for 30 s and 74°C for 4 min. Primers used for GAPDH were used as a loading control (forward strand, 5#-ACCACAGTCCATGCCATCAC-3# and reverse strand, 5#-TCCACCACCCTGTTGCTGTA-3#).
Nuclear-cytoplasmic fractionation, western blotting analysis and immunoprecipitation Cytoplasmic-and nuclear-enriched fractions were prepared by scraping 5 Â 10 6 cells in 1.5 ml of hypotonic lysis buffer consisting of 10 mM N-2-hydroxyethylpiperazine-N#-2-ethanesulfonic acid (pH 7.9), 2.5 mM MgCl 2 , 0.2 mM ethylenediaminetetraacetic acid, 0.5 mM dithiothreitol, 40 mM NaF, 4 mM b-glycerophosphate, 0.2% Nonidet P-40, 0.5 mM phenylmethylsulfonyl fluoride, 0.5 mM benzamidine HCl and 2 lg/ml each aprotinin and leupeptin.
Cells suspension was maintained on ice for 20 min and inverted several times. The nuclear fraction (P1) was isolated by centrifugation of the suspension at 3500g for 5 min, followed by washing in 0.5 ml of hypotonic buffer. The supernatant, representative of cytoplasmic fraction (S1), was added with NaCl to 0.14 M final concentration and clarified by 10 min centrifugation at 10 000g. Nuclear proteins were extracted from nuclear fraction by lysis in 0.3 ml hypertonic lysis buffer (50 mM Tris-HCl, 0.14 M NaCl, 0.25 M KCl, 1 mM ethyleneglycol-bis(aminoethylether)-tetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.5 mM dithiothreitol, plus protease and phosphatase inhibitors), followed by 1 h rotation at 4°C, and clarified by 10 min centrifugation at 10 000g. Respectively, 50 lg of cytoplasmic and 30 lg of nuclear proteins were analyzed by western blotting and probed to specific antibodies. Phospho-SMAD2, phospho-Akt, ERK1/2 and phospho-ERK1/2 1:1000 (Cell Signaling Technology, Danvers, MA); SMAD2 1:1000 (BD Transduction Laboratories, San Diego, CA); SMAD4 (1 lg/ml Upstate Biotechnology, Lake Placid, NY); Akt 1:200 and PTEN 1:500 (Santa Cruz Biotechnology, Santa Cruz, CA); a-tubulin, histone H1 1:500 (Santa Cruz Biotechnology) and GAPDH 1:5000 (Ambion, Austin, TX) antibodies were utilized.
For total lysates, cells were washed three times with ice-cold phosphatebuffered saline, and the cells lysed using total lysis buffer (150 mM NaCl, 10 mM Tris-HCl, pH 7.8, 1 mM ethylenediaminetetraacetic acid, 0.5% Triton X-100, 1 mM sodium orthovanadate) containing protease inhibitors (1 lg/ml leupeptin and 100 lg/ml phenylmethylsulfonyl fluoride). Cells were then incubated at 4°C for 30 min with constant shaking, then scraped into microcentrifuge tubes and centrifuged at 12 000g for 15 min to remove insoluble material. The protein content in each sample was determined and adjusted. For immunoprecipitation, lysates were incubated with the immunoprecipitating antibody for 1 h at 4°C, followed by another 1 h incubation with protein A-agarose again at 4°C. Pellets were treated with 2Â loading buffer (50 mM Tris, pH 6.8, 2% sodium dodecyl sulfate, 100 mM dithiothreitol, 0.2% bromophenol blue, 20% glycerol) and boiled for 5 min. Loading buffer supernatants from immunoprecipitation studies or cell lysates were then re-suspended in 2Â gel loading buffer, boiled for 5 min and then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (9% polyacrylamide). Resolved proteins were transferred overnight at 4°C onto a polyvinylidene difluoride membrane (Millipore Corporate, Billerica, MA), blocked with a 5% solution of skim milk for 30 min at room temperature, followed by further incubation with monoclonal antibodies to specific antibodies. After washing with phosphate-buffered saline with 1% Tween, the secondary antibody was applied to the membrane. After washing with PBS with 1% Tween, the membrane was treated with a chemiluminescent solution according to manufacturer's instructions and exposed to X-ray film. Densitometric analysis of the blots was performed using an AlphaImager digital imaging system (Alpha Innotech Corporation, San Leandro, CA).
Data analysis
All data are expressed as the means for a series of experiments ± SEM. Data were analyzed by either one-way analysis of variance followed by StudentNewman-Keul's post hoc test or by Student's t-tests for unpaired samples using Instat 3.0 (San Diego, CA). P , 0.05 was considered statistically significant.
Results
TGFb mediates SMAD2 activation and nuclear translocation in SMAD4-null and ERK activated BxPc-3 and CAPAN-1 cells TGFb1 signaling usually requires SMAD4 together with SMAD2 activation, and nuclear translocation to transmit the TGFb1-SMADresponsive signaling event. To assess if TGFb1 could mediate SMAD2 translocation in SMAD4-null cells, we treated BxPc-3 and CAPAN-1 cells with TGFb, and observed SMAD compartmentalization using western blots after cytoplasmic/nuclear separation. As shown in Figure 1 , TGFb1 (10 ng/ml) caused activation and translocation of SMAD2 in WT-K-RAS BxPc-3 pancreatic cancer and oncogenic K-RAS CAPAN-1 cells. To address if activated RAS/ ERK affected TGFb-SMAD signaling, we inhibited MEK with the pharmacologic inhibitor, PD98059, which is activated downstream of K-RAS, and inhibited K-RAS itself with a DN-K-RAS construct. Pretreatment of CAPAN-1 cells with PD98059 or with transfection with the DN-RAS construct (Figure 2A) , or pre-treatment of BxPc-3 cells with PD98059 ( Figure 2B ) in the presence of TGFb markedly improved SMAD2 activation and translocation. Note that SMAD4 protein was not detectable which further confirmed that the cells are (Figure 3) . We observed minimal reduction of PTEN mRNA levels after 3 and 6 h of TGFb1 treatment as compared with the untreated control. However, beginning at 6 h in BxPC-3 cells and by 24 h incubation with TGFb1, a significant reduction of amplifiable PTEN mRNA was observed in both pancreatic cancer cell lines that recovered to some degree by 48 h after treatment (Figure 3) . To verify the PTEN mRNA findings, we then examined the steadystate levels of PTEN protein. At the protein level in BxPc-3 cells, PTEN protein was also present and unchanged from controls through 24 h after TGFb1 treatment ( Figure 4A ). However, PTEN protein expression was reduced by 48 h after treatment in BxPc-3 ( Figure 4A ) and CAPAN-1 cells (not shown, but 48 h data shown in Figure 6B ), following the reduced PTEN mRNA expression at 24 h. Therefore, TGFb1 appears to mediate suppression of PTEN mRNA and protein in a SMAD4-independent manner. PTEN function antagonizes PI3K function, and one of the effectors of PI3K, Akt (25) . To assess whether the TGFb-induced reduction in PTEN expression coincides with an imbalance in function of PI3K, we determined the activation of phospho-Akt at the same time PTEN protein is suppressed. As shown in Figure 4B , the suppression of PTEN by TGFb is simultaneous with Akt activation, demonstrating functional loss of PTEN.
Modulation of TGFb-induced PTEN suppression by RAS/ERK constitutes an 'on/off' switch As the RAS/ERK pathway is activated in pancreatic cancers, we assessed if RAS/ERK modulates the TGFb-induced PTEN suppression observed in the SMAD4-null cell lines. PD98059, the MEK inhibitor, had no effect on amplifiable, semi-quantitative PTEN mRNA alone in CAPAN-1 ( Figure 5A ) and had no statistical significance to the small observed increase in PTEN mRNA in BxPc-3 cells with 50 lM PD98059 ( Figure 5B ). Treatment with PD98059, however, rescued TGFb-induced PTEN mRNA suppression ( Figure 5A and B). Similarly at the protein level, PD98059 had no effect on PTEN protein alone ( Figure 6A ). However, PD98059 reversed TGFb-induced PTEN protein suppression ( Figure 6A ). Additionally, CAPAN-1 cells transfected with DN-K-RAS and treated with TGFb for 48 hreversed the TGFb-induced PTEN suppression ( Figure 6B ). Thus, RAS/ERK appears to facilitate TGFb-induced PTEN suppression as blockage of ERK or RAS restores PTEN expression to pre-treatment levels. Here, RAS/ERK can 'switch' PTEN off through TGFb signaling when activated and restore PTEN to 'on' through TGFb signaling when RAS/ ERK is inactivated.
TGFb-induced pancreatic cancer cell proliferation parallels PTEN expression and modulation by RAS/ERK
We assessed the biological consequences of modulation of TGFbinduced PTEN suppression in the SMAD4-null pancreatic cancer cell lines. Cells were incubated with TGFb at concentrations shown to suppress PTEN expression both at protein and mRNA levels. As shown in Figure 7 , addition of TGFb for 72 h significantly affects cell growth. TGFb treatment causes pancreatic cell proliferation when compared with cells that were not treated with TGFb. We then examined the effect of ERK by inhibiting its upstream inducer MEK1 using (A and B) , or transiently transfected with a DN construct of K-RAS (A) 48 h before treatment with TGFb. Cell lysates were blotted with anti-phospho-SMAD2, tubulin and histone antibodies. Note that PD98059 and DN-K-RAS transfection improved TGFb-induced p-SMAD2 nuclear translocation. Tubulin served as a loading control and indicated purity of the cytoplasmic fractions, whereas histone served as a loading control and purity of the nuclear fractions. 
RAS/ERK modulates TGFb-induced PTEN expression
PD98059, using three increasing concentrations for inhibition. As shown in Figure 7 , PD98059 (12.5 lM to 50 lM) caused a dosedependent reduction in cell growth with TGFb treatment. With increasing blockade of MEK1/ERK, TGFb-induced proliferation was converted to TGFb-induced growth suppression. Thus, the RAS/ERK pathway contributes to the ability of SMAD4-null pancreatic cancer cells to proliferate. RAS/ERK also modulates TGFb-induced proliferation, which is paralleled by modulation of TGFb-induced PTEN expression.
Discussion
Our investigation links two commonly affected signaling pathways in pancreatic cancer in the regulation of the tumor suppressor PTEN. PTEN mRNA suppression by TGFb was first described in keratinocytes when PTEN was originally cloned (34) , but the mechanisms for TGFb-induced PTEN regulation had not been examined. On the other hand, PTEN expression blocked TGFb-mediated cell invasion whereas PTEN absence increases TGFb-induced invasion (38) . The effects might be mediated by SMAD3, as this intracellular signaling molecule inducibly interacts with PTEN (38) . PTEN is commonly affected in multiple cancers, often inactivated by genetic (23, 24, 33) or epigenetic (39) events during the pathogenesis of a particular cancer. This does not appear to be the case in pancreatic adenocarcinoma. PTEN protein expression in pancreatic cancers has previously been shown via immunohistochemistry to be reduced (35), but not due to genetic events (33) . Here, we demonstrate that (i) TGFb suppresses PTEN expression in SMAD4-null cells at the transcriptional level with subsequent reduction in protein expression and simultaneous increase in phospho-Akt; (ii) RAS/ERK signaling interferes with TGFb-SMAD nuclear translocation, and SMAD2 translocation is improved Taken together, our findings have a number of implications in pancreatic adenocarcinoma. First, we implicate PTEN, as regulated by TGFb, as a controller of cellular proliferation in pancreatic cancer. Thus, PTEN through ligand regulation, in addition to genetic and epigenetic events, contributes to cancer growth. Regulation of PTEN by TGFb is complex as this regulation occurs in SMAD4-null cells. As depicted in Figure 8 , we speculate that there are at least two intracellular pathways by which TGFb regulates PTEN. With TGFbmediated SMAD-dependent signaling, a well-characterized suppressor pathway in epithelial cells, we suggest that this cascade enhances PTEN expression. In our pancreatic cell models studied, PTEN expression is lessened by (i) loss of SMAD4, which is well-described to facilitate translocation of SMAD2 into the nucleus; and (ii) interference of SMAD2 translocation by activated RAS/ERK, which has been suggested to phosphorylate the linker region of SMAD2/3 and prohibits its translocation to the nucleus (22) . Because SMAD2 translocation was improved with blockage of RAS/ERK, as well as restoration of TGFb-induced PTEN expression, SMAD2 may have nuclear effects that are independent of the presence of SMAD4, and this has been suggested in the literature (40, 41) .
Second, we also speculate the presence of a TGFb-mediated SMAD-independent pathway, which down-regulates PTEN and facilitates cellular growth. Our data strongly suggest the existence of such a pathway because TGFb mediates PTEN suppression in the absence of SMAD4 and in the presence of activated RAS/ERK, both of which attenuate SMAD2 nuclear translocation. Thus, SMAD-dependent signaling is blocked, which is the case in most human pancreatic cancers, while TGFb still has cellular effects. There are a number of reports that indicate that TGFb can have dual roles: growth suppression and, in the right scenario, induce growth proliferation. In many cases, TGFb's role in cellular proliferation is demonstrated in metastasis, which represents mature cancers with the accumulated pathway derangements. In pancreatic cancers, TGFb ligand is often up-regulated, and this is believed to be due to loss of negative feedback regulation by SMAD-dependent signaling (35) . The increased amounts of ligand could help increasingly signal through a proliferative-driven SMADindependent pathway through down-regulation of PTEN favoring unbalanced mitogenic PI3K signaling. Recently, a second mechanism has been demonstrated that reduces PTEN levels after TGFb stimulation. TGFb signaling induces dephosphorylation of PTEN, reducing its stability in the cytoplasm (42) . Thus, there appears to be at least two mechanisms, reduced PTEN expression and reduced PTEN stability, to decrease PTEN protein levels to increase the pancreatic cancer cell's ability to proliferate with TGFb signaling.
Third, RAS/ERK, which is activated in over 90% of pancreatic cancers, modulates PTEN expression through TGFb signaling. The regulation appears to be through blocking SMAD translocation, as Ã P , 0.05 versus control and yP , 0.05 versus TGFb treatment alone. Fig. 7 . Effect of TGFb and RAS/ERK inhibition on BxPc-3 cell growth. BxPC-3 cells were plated in complete medium (supplemented with 10% fetal bovine serum). Cells were then grown in serum-free medium (serum depleted) in control medium, in medium containing 10 ng/ml TGFb alone, or TGFb in the presence of 12.5-50 lM PD98059. Cell number was determined on day 3. Data shown are means ± SEM of 12 independent assays and normalized to controls.
Ã P , 0.05 and ÃÃ P , 0.01 versus cells without TGFb treatment; yP , 0.05, yyP , 0.01 and yyyP , 0.001 versus cells with TGFb but no PD98059 inhibitor treatment.
RAS/ERK modulates TGFb-induced PTEN expression
previously suggested in the literature (22) . However, K-RAS mutations, in particular, are one of the earliest events in pancreatic cancer pathogenesis, and oncogenic mutations are seen in benign pancreatic conditions such as pancreatitis (18, 19) . Because RAS/ERK activation is a potent inhibitor of SMAD signaling, TGFb-induced PTEN regulation is likely affected at a very early stage in pancreatic carcinogenesis.
In summary, we indicate that PTEN may be a key tumor suppressor involved in pancreatic tumorigenesis. Unlike other tumors in which PTEN is inactivated by a variety of genetic or epigenetic mechanisms, PTEN expression is ligand regulated by TGFb signaling. The TGFbinduced PTEN expression may be determined by either or both of SMAD-dependent and SMAD-independent signaling pathways. When SMAD-dependent signaling is blocked by oncogenic K-RAS or activated ERK, TGFb induces down-regulation of PTEN coupled with growth proliferation of pancreatic cells. When RAS/ERK activation is blocked, SMAD2 nuclear translocation is restored (even without SMAD4), TGFb-induced PTEN down-regulation is reversed and cellular proliferation is reduced to non-TGFb-induced levels. We suggest that RAS/ERK activation 'switches' the balance of the dual roles of TGFb in favor of proliferation when PTEN is turned off, and the switch can be reversed with blockage of RAS/ERK to turn PTEN expression on reducing cellular proliferation. This regulatory mechanism could potentially be controlled pharmacologically.
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